GXIPC1®

In people with diabetes, pancreatic beta-cells either fail to produce enough insulin (insulin deficiency) or insulin function deteriorates (insulin  resistance), leading to elevated blood sugar levels and diabetes. Current treatments can only control the condition and require lifelong medication or insulin injections, but can barely cure it. While pancreas transplantation is a potential solution, it is a complex procedure with no guarantee of success, so the development of more convenient, directly applicable treatments is critical.

GWOXI's new drug "GXIPC1®" has been experimentally proven to effectively improve diabetes by controlling blood sugar levels and maintaining the number and intact form of pancreatic islets. This research has been awarded a patent for the invention.

In 2019, Gwo Xi entered into a joint venture with a medical institution affiliated with Vietnam'sVinmec Group Medical Institution to develop a stem cell new drug for treating diabetes and carry out a clinical trial in Vietnam. In July 2021, we have received approval from the Vietnamese Ministry of Health (MOH) to conduct a Phase I clinical trial for treating diabetes (NCT05308836), and have now completed phase I clinical trial’s recruitment, becoming an unprecedented trial of exporting stem cells overseas for treating diabetes, establishing a landmark for international cold chain delivery of cell therapy product.